FDA MEDIA ADVISORY
For Planning Purposes Only

May 11, 2021

FDA Press Conference:
Authorization of Pfizer COVID-19 Vaccine
for Use in Adolescents

Pre-registration is required. Use the link below.
This press conference is for student media only.

The U.S. Food and Drug Administration (FDA) invites you to join us for a virtual press conference via a Zoom call about its authorization of the Pfizer COVID-19 Vaccine for use in adolescents.

This press conference is for high school and middle school journalists and will be live streamed over the FDA’s YouTube channel.

To participate in the press conference, we ask you to join the Zoom virtual press conference on camera so that the FDA speakers and other viewers may see you as you ask questions. Student reporters who ask questions will appear on the screen to the speakers and the public. Your image will also be broadcast via the FDA YouTube live stream.

To watch only, you can view the FDA YouTube live stream.

What

A virtual press conference with the FDA to discuss the authorization of the Pfizer COVID-19 Vaccine for use in adolescents. The FDA wants to offer this opportunity for student media to hear directly from FDA leadership about the vaccine and what young people should know.

Who

Janet Woodcock, M.D., acting FDA commissioner

Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research

When

3:30 p.m. ET Tuesday, May 18, 2021

Register here.

Use this link to register for the press conference.

Registration is required to join the press conference. Registration is limited to student journalists only. The confirmation email you will receive will contain the link to join the press conference via Zoom, which will then be broadcast on YouTube.

TO PARTICIPATE & ASK QUESTIONS
Register to join the Zoom press conference and ask questions.

TO WATCH THE PRESS CONFERENCE ONLY
No registration required. It will be live streamed on the FDA’s YouTube channel.

QUESTIONS ABOUT THE PRESS CONFERENCE
Contact the FDA’s Office of Media Affairs, at fdaoma@fda.hhs.gov.